乳腺癌中常有PI3K/Akt/mTOR信号通路的异常,现有的证据提示,PI3K/Akt/mTOR是促进细胞增殖、代谢、存活、转移以及抗肿瘤治疗耐药等功能的重要信号通路之一,该通路中的生物标记物可能预测联合雷帕霉素靶蛋白(mammalian target of rapamy...乳腺癌中常有PI3K/Akt/mTOR信号通路的异常,现有的证据提示,PI3K/Akt/mTOR是促进细胞增殖、代谢、存活、转移以及抗肿瘤治疗耐药等功能的重要信号通路之一,该通路中的生物标记物可能预测联合雷帕霉素靶蛋白(mammalian target of rapamycin,mTOR)抑制剂的乳腺癌治疗的临床疗效,本文就此作一回顾性论述。展开更多
目的:研究筋骨草总环烯醚萜(iridoids in Ajuga decumbens,ADI)对乳腺癌干细胞特性的干预作用及分子机制。方法:采用无血清悬浮微球体形成实验,transwell迁移和侵袭实验检测乳腺癌干细胞自我更新能力、运动和侵袭能力。流式细胞法分...目的:研究筋骨草总环烯醚萜(iridoids in Ajuga decumbens,ADI)对乳腺癌干细胞特性的干预作用及分子机制。方法:采用无血清悬浮微球体形成实验,transwell迁移和侵袭实验检测乳腺癌干细胞自我更新能力、运动和侵袭能力。流式细胞法分析CD44+CD24-/low细胞亚群比例。蛋白免疫印迹法(Western blot)检测肿瘤干细胞干性相关蛋白,细胞外信号调节激酶(ERK)和磷脂酰肌醇3激酶(PI3K)/蛋白激酶B(PKB或Akt)信号通路相关蛋白的表达。结果:5~80 mg·L-1ADI能浓度依赖性降低乳腺癌MCF-7细胞微球体形成的数量和体积,减少CD44+CD24-/low细胞亚群比例(P〈0.05,P〈0.01)。10~40 mg·L-1ADI对乳腺癌MCF-7干细胞的迁移和侵袭能力有明显抑制作用(P〈0.05,P〈0.01)。进一步研究发现,ADI能明显降低p-ERK,p-Akt,干性标志物八聚体结合转录因子-3/4(Oct-3/4),SRY相关的HMG盒转录因子-2(Sox-2)和胚胎干细胞转录因子(Ecat4或Nanog)蛋白表达(P〈0.05,P〈0.01)。结论:筋骨草总环烯醚萜能有效地抑制乳腺癌干细胞的自我更新和转移潜能等"干性"特性,作用机制可能与其调控ERK1/2丝裂原活化蛋白激酶(MAPK)和PI3K/Akt信号通路,下调相关干性标志物表达有关。展开更多
Objective: To investigate the effects of CAL-101, particularly when combined with bortezomib(BTZ) on mantle cell lymphoma(MCL) cells, and to explore its relative mechanisms.Methods: MTT assay was applied to detect the...Objective: To investigate the effects of CAL-101, particularly when combined with bortezomib(BTZ) on mantle cell lymphoma(MCL) cells, and to explore its relative mechanisms.Methods: MTT assay was applied to detect the inhibitory effects of different concentrations of CAL-101. MCL cells were divided into four groups: control group, CAL-101 group, BTZ group, and CAL-101/BTZ group. The expression of PI3K-p110σ, AKT, ERK, p-AKT and p-ERK were detected by Western blot. The apoptosis rates of CAL-101 group, BTZ group, and combination group were detected by flow cytometry. The location changes of nuclear factor kappa-B(NF-κB) of 4 groups was investigated by NF-κB Kit exploring. Western blot was applied to detect the levels of caspase-3 and the phosphorylation of AKT in different groups. Results: CAL-101 dose- and time-dependently induced reduction in MCL cell viability. CAL-101 combined with BTZ enhanced the reduction in cell viability and apoptosis. Western blot analysis showed that CAL-101 significantly blocked the PI3K/AKT and ERK signaling pathway in MCL cells. The combination therapy contributed to the inactivation of NF-κB and AKT in MCL cell lines. However, cleaved caspase-3 was up-regulated after combined treatment. Conclusion: Our study showed that PI3K/p110σ is a novel therapeutic target in MCL, and the underlying mechanism could be the blocking of the PI3K/AKT and ERK signaling pathways. These findings provided a basis for clinical evaluation of CAL-101 and a rationale for its application in combination therapy, particularly with BTZ.展开更多
文摘乳腺癌中常有PI3K/Akt/mTOR信号通路的异常,现有的证据提示,PI3K/Akt/mTOR是促进细胞增殖、代谢、存活、转移以及抗肿瘤治疗耐药等功能的重要信号通路之一,该通路中的生物标记物可能预测联合雷帕霉素靶蛋白(mammalian target of rapamycin,mTOR)抑制剂的乳腺癌治疗的临床疗效,本文就此作一回顾性论述。
基金supported by the National Natural Science Foundation of China (Grant No. 30672208, 81270603, and 31301161) Tianjin Natural Science Foundation of China (Grant No. 13JCYBJC22800)
A
文摘Objective: To investigate the effects of CAL-101, particularly when combined with bortezomib(BTZ) on mantle cell lymphoma(MCL) cells, and to explore its relative mechanisms.Methods: MTT assay was applied to detect the inhibitory effects of different concentrations of CAL-101. MCL cells were divided into four groups: control group, CAL-101 group, BTZ group, and CAL-101/BTZ group. The expression of PI3K-p110σ, AKT, ERK, p-AKT and p-ERK were detected by Western blot. The apoptosis rates of CAL-101 group, BTZ group, and combination group were detected by flow cytometry. The location changes of nuclear factor kappa-B(NF-κB) of 4 groups was investigated by NF-κB Kit exploring. Western blot was applied to detect the levels of caspase-3 and the phosphorylation of AKT in different groups. Results: CAL-101 dose- and time-dependently induced reduction in MCL cell viability. CAL-101 combined with BTZ enhanced the reduction in cell viability and apoptosis. Western blot analysis showed that CAL-101 significantly blocked the PI3K/AKT and ERK signaling pathway in MCL cells. The combination therapy contributed to the inactivation of NF-κB and AKT in MCL cell lines. However, cleaved caspase-3 was up-regulated after combined treatment. Conclusion: Our study showed that PI3K/p110σ is a novel therapeutic target in MCL, and the underlying mechanism could be the blocking of the PI3K/AKT and ERK signaling pathways. These findings provided a basis for clinical evaluation of CAL-101 and a rationale for its application in combination therapy, particularly with BTZ.